SG11201805591QA - Tacrolimus for treating tdp-43 proteinopathy - Google Patents
Tacrolimus for treating tdp-43 proteinopathyInfo
- Publication number
- SG11201805591QA SG11201805591QA SG11201805591QA SG11201805591QA SG11201805591QA SG 11201805591Q A SG11201805591Q A SG 11201805591QA SG 11201805591Q A SG11201805591Q A SG 11201805591QA SG 11201805591Q A SG11201805591Q A SG 11201805591QA SG 11201805591Q A SG11201805591Q A SG 11201805591QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tacrolimus
- rdc5
- proteinopathy
- street
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization International Bureau .. .... ..Yejd (43) International Publication Date ..... .....1 13 July 2017 (13.07.2017) WI P0 I P CT IIIM141101110101011111 HO 11111011130111111111111110011111111101111 III N (10) International Publication Number WO 2017/118857 Al (51) (21) (22) (25) (26) (30) (71) (72) (74) International Patent Classification: A61K 31/436 (2006.01) A61P 25/28 (2006.01) International Application Number: International Filing Date: Filing Language: Publication Language: Priority Data: 1600376.6 8 January 2016 (81) Designated States (unless otherwise indicated, for every A61P 25/16 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/GB2017/050021 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 6 January 2017 (06.01.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (08.01.2016) GB (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, LIMITED GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 41 Cornmarket Street, Oxford TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Pete; 40 Castle Road, Woot- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, JONES, Huw; The Old SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Morden, Royston Hert- GW, KM, ML, MR, NE, SN, TD, TG). Helen; 14 Somer- (GB). SHERRIFF, Julia; 5 Published: 8FF (GB). — with international search report (Art. 21(3)) Potter Clarkson LLP, Street, Nottingham NG1 5GG Applicant: CHRONOS THERAPEUTICS [GB/GB]; c/o Mercer Lewin, OX1 3HA (GB). Inventors: APPLEFORD, ton, Woodstock OX20 lEG (GB). School, 45 Church Street, Guilden fordshire SG8 OJD (GB). KUHLMAN, dale View, Bath BA2 2QQ Terrett Avenue, Oxford OX3 Agent: CARLING, David Andrew; The Belgrave Centre, Talbot (GB). Title: TACROLIMUS FOR TREATING TDP-43 PROTEINOPATHY 300 250 W — 200, >+ cu ... as 150 —I 100 50 : The present invention as amyotrophic lateral sclerosis (ALS) and frontotemporal dementias (FTDs), wherein the tacrolimus is for administration at a -effective dose which (54) \" therapeutically Rotarod Performance over 60 weeks V 4 f 4—. - — RDC5 0 25mg/kg — RDC5 1 25mg/kg R . ' T T1 — RDC5 2 5mg/kg I — Vehicle 1 — Non Tg TT T TT f i. l' k'`w r . Il .4 Ir ... ' 11 in GC Il Il IN 1-1 (57) 0 such 0 10 20 30 40 50 60 70 Week FIGURE 3 provides tacrolimus for use in the treatment in a human subject of a TDP-43 proteinopathy, does not cause immunosuppression in the subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1600376.6A GB201600376D0 (en) | 2016-01-08 | 2016-01-08 | Novel therapeutic agents |
PCT/GB2017/050021 WO2017118857A1 (en) | 2016-01-08 | 2017-01-06 | Tacrolimus for treating tdp-43 proteinopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805591QA true SG11201805591QA (en) | 2018-07-30 |
Family
ID=55445754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805591QA SG11201805591QA (en) | 2016-01-08 | 2017-01-06 | Tacrolimus for treating tdp-43 proteinopathy |
Country Status (10)
Country | Link |
---|---|
US (1) | US20190015395A1 (en) |
EP (1) | EP3399977A1 (en) |
JP (1) | JP2019501972A (en) |
KR (1) | KR20180102086A (en) |
CN (1) | CN108601772A (en) |
AU (1) | AU2017205162A1 (en) |
CA (1) | CA3010203A1 (en) |
GB (1) | GB201600376D0 (en) |
SG (1) | SG11201805591QA (en) |
WO (1) | WO2017118857A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10752642B1 (en) | 2019-04-30 | 2020-08-25 | George Mason University | Macrocyclic lactones |
US11666560B2 (en) | 2020-09-24 | 2023-06-06 | George Mason University | Anti-fibrotic agent |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8728820D0 (en) | 1987-12-09 | 1988-01-27 | Fisons Plc | Compounds |
GB2279006A (en) * | 1993-06-03 | 1994-12-21 | Fujisawa Pharmaceutical Co | Treatment of amyotrophic lateral sclerosis |
US5898029A (en) * | 1994-04-12 | 1999-04-27 | The John Hopkins University | Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors |
BRPI0413927B8 (en) | 2003-08-29 | 2021-05-25 | Lifecycle Pharma As | pharmaceutical composition comprising tacrolimus, dosage form, use of the composition, and method for preparing the composition |
EP2167033B1 (en) | 2007-05-30 | 2017-04-19 | Veloxis Pharmaceuticals A/S | Once daily oral dosage form comprising tacrolimus |
RU2574006C2 (en) | 2008-07-08 | 2016-01-27 | Лайфсайкл Фарма А/С | Tacrolimus for improved treatment of patients with grafts |
LT2575769T (en) | 2010-02-17 | 2016-10-10 | Veloxis Pharmaceuticals A/S | Stabilized tacrolimus composition |
GB201309375D0 (en) * | 2013-05-24 | 2013-07-10 | Chronos Therapeutics Ltd | Medical methods and compounds for medical use |
-
2016
- 2016-01-08 GB GBGB1600376.6A patent/GB201600376D0/en not_active Ceased
-
2017
- 2017-01-06 KR KR1020187019418A patent/KR20180102086A/en unknown
- 2017-01-06 CN CN201780005933.1A patent/CN108601772A/en active Pending
- 2017-01-06 CA CA3010203A patent/CA3010203A1/en not_active Abandoned
- 2017-01-06 WO PCT/GB2017/050021 patent/WO2017118857A1/en active Application Filing
- 2017-01-06 EP EP17703204.2A patent/EP3399977A1/en not_active Withdrawn
- 2017-01-06 US US16/068,558 patent/US20190015395A1/en not_active Abandoned
- 2017-01-06 SG SG11201805591QA patent/SG11201805591QA/en unknown
- 2017-01-06 JP JP2018555308A patent/JP2019501972A/en active Pending
- 2017-01-06 AU AU2017205162A patent/AU2017205162A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20190015395A1 (en) | 2019-01-17 |
AU2017205162A1 (en) | 2018-07-26 |
KR20180102086A (en) | 2018-09-14 |
EP3399977A1 (en) | 2018-11-14 |
GB201600376D0 (en) | 2016-02-24 |
WO2017118857A1 (en) | 2017-07-13 |
CN108601772A (en) | 2018-09-28 |
JP2019501972A (en) | 2019-01-24 |
CA3010203A1 (en) | 2017-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900596XA (en) | Cannabis composition | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201810161RA (en) | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases | |
SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201900501RA (en) | Cannabis composition | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201808220VA (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
SG11201808949SA (en) | Combinations and methods comprising a capsid assembly inhibitor | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |